QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 protagenic-therapeutics-reports-safety-data-from-single-dose-portion-of-phase-1-trial-involving-pt00114

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence

 protagenic-therapeutics-peptide-pt00114-to-be-highlighted-at-boston-summit-in-presentation-titled-novel-blood-brain-barrier-penetrating-peptide-opening-new-doors-in-neuro-psychiatric-treatment-on-april-23-2024

Chief Operating Officer to Present Key Advances at Peptide Therapeutics SummitNEW YORK, NY / ACCESSWIRE / April 17, 2024 / Prot...

 protagenic-therapeutics-q4-eps-038-down-from-014-yoy

Protagenic Therapeutics (NASDAQ:PTIX) reported quarterly losses of $(0.38) per share. This is a 171.43 percent decrease over lo...

 earnings-scheduled-for-april-1-2024

Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per...

 protagenic-therapeutics-successfully-concludes-third-cohort-in-single-dose-portion-of-phase-1-trial-for-stress-related-neuropsychiatric-disorders

Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. ...

 protagonist-reports-2-year-follow-up-data-from-rusfertide-revive-study-at-the-ash-annual-meeting

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from five abstracts at the Am...

 stocks-that-hit-52-week-lows-on-tuesday

  Tuesday saw 132 companies set new 52-week lows.